Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


First published on November 15, 2006
A more recent version of this article appeared on January 1, 2007
Neuro Oncol 2006, DOI:10.1215/15228517-2006-026
This Article
Right arrow Advance Publication Full Text (PDF)
Right arrow All Versions of this Article:
9/1/39    most recent
15228517-2006-026v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mora, J.
Right arrow Articles by Navarro, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Copyright 2006 by the Society for Neuro-Oncology

Received June 16, 2006
Accepted September 25, 2006

Clinical Investigations

Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin

Jaume Mora 1*, Ofelia Cruz 1, Sandra Gala 1, Ramon Navarro 2

1 Department of Pediatric Oncology, Hospital Sant Joan de Déu, Barcelona, Spain
2 Department of Neurosurgery, Hospital Sant Joan de Déu, Barcelona, Spain

* To whom correspondence should be addressed. E-mail: Jmora{at}hsjdbcn.org.


   Abstract

Childhood spinal cord astrocytomas are rare diseases, and their management is controversial. We report here our successful experience using irinotecan and cisplatin in three consecutive infants with progressing intramedullary astrocytomas. The first patient was a 16-month-old girl who presented with a grade III intramedullary astrocytoma that rapidly progressed after surgery and adjuvant chemotherapy. Weekly irinotecan (50 mg/m2) and cisplatin (30 mg/m2) for four consecutive weeks (one cycle) for a total of four cycles (I/C regimen) was used in order to avoid or delay radiotherapy. Radiological complete remission was achieved 10 months after completion of therapy, and 3.5 years after diagnosis the patient remains disease free. The second patient was a 19-month-old boy with a C3-T4 grade II intramedullary astrocytoma who received up-front vincristine and carbo­platin for two months but remained clinically symptomatic. A follow-up MRI showed a larger tumor, and the patient was switched to the I/C regimen. A marked clinical improvement occurred after the first cycle, and MRI showed a very good partial remission at the end of therapy. At 16 months after diagnosis, the patient remains disease free. The third patient was a 10-month-old girl with a C2-T3 grade II intramedullary astrocytoma. She presented with severe pain that became steroid dependent during the month she was treated with the vincristine-carboplatin regimen. When she was switched to the I/C regimen, the clinical symptoms responded within days. MRI at the end of therapy showed a significant reduction in tumor size, and one year after diagnosis the patient remains symptom free. Using this I/C regimen for childhood intramedullary astrocytoma, we obtained remarkable clinicoradiological responses while avoiding the use of radiotherapy.

Key Words: chemotherapy, childhood brain tumor, cisplatin, intramedullary astrocytoma, irinotecan, primary intramedullary spinal cord neoplasms


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


Copyright 2006 by Society for Neuro-Oncology